OneDigital Investment Advisors LLC Makes New Investment in CVS Health Corporation $CVS

OneDigital Investment Advisors LLC purchased a new stake in CVS Health Corporation (NYSE:CVS) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 159,641 shares of the pharmacy operator’s stock, valued at approximately $16,515,000.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of CVS Health by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator’s stock worth $9,579,508,000 after acquiring an additional 1,824,424 shares during the period. State Street Corp raised its position in CVS Health by 2.1% in the fourth quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock worth $4,776,182,000 after acquiring an additional 1,245,457 shares in the last quarter. Capital International Investors lifted its holdings in CVS Health by 3.4% in the fourth quarter. Capital International Investors now owns 27,592,356 shares of the pharmacy operator’s stock valued at $2,189,793,000 after acquiring an additional 900,153 shares during the period. Norges Bank purchased a new stake in shares of CVS Health during the 4th quarter worth $1,666,265,000. Finally, Morgan Stanley boosted its position in shares of CVS Health by 6.3% during the 4th quarter. Morgan Stanley now owns 20,373,774 shares of the pharmacy operator’s stock worth $1,616,863,000 after purchasing an additional 1,211,631 shares in the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Trading Down 0.1%

Shares of CVS opened at $97.09 on Monday. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66. CVS Health Corporation has a 1-year low of $67.42 and a 1-year high of $110.68. The stock has a market cap of $124.18 billion, a price-to-earnings ratio of 25.69, a price-to-earnings-growth ratio of 0.93 and a beta of 0.61. The firm has a 50 day simple moving average of $102.52 and a 200-day simple moving average of $88.26.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $1.87 by $0.71. The firm had revenue of $106.10 billion for the quarter, compared to analysts’ expectations of $100.03 billion. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.CVS Health’s quarterly revenue was up 7.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Equities analysts forecast that CVS Health Corporation will post 8.02 EPS for the current fiscal year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date was Thursday, July 23rd. CVS Health’s dividend payout ratio (DPR) is currently 70.37%.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Royal Bank Of Canada increased their price target on shares of CVS Health from $107.00 to $113.00 and gave the company an “outperform” rating in a report on Thursday, July 9th. JPMorgan Chase & Co. boosted their price objective on shares of CVS Health from $111.00 to $118.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Mizuho upped their target price on shares of CVS Health from $110.00 to $115.00 and gave the stock an “outperform” rating in a research report on Monday, June 8th. UBS Group lifted their price target on shares of CVS Health from $122.00 to $126.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Finally, Piper Sandler reissued an “overweight” rating and set a $113.00 price target on shares of CVS Health in a research note on Monday, June 1st. Twenty-two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, CVS Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $106.75.

Insider Buying and Selling

In related news, Director Larry Robbins sold 370,462 shares of the business’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the transaction, the director owned 4,824,799 shares of the company’s stock, valued at approximately $450,877,466.55. The trade was a 7.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last three months, insiders sold 3,372,000 shares of company stock worth $317,473,598. Company insiders own 0.85% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.